Skip to main content
Terug
Watch Compare

KYNTRA BIO, INC.

Datakwaliteit: 100%
KYNB
NASDAQ Manufacturing Chemicals
€ 7,17
▼ € 0,02 (-0,28%)
Marktkapitalisatie: 29,10 M
Prijs
€ 7,19
Marktkapitalisatie
29,10 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Revenue declined -59,33% annually over 5 years
Net margin of 2848,63% shows strong profitability
Negative free cash flow of -4,81 M
P/E of 0,16 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 18,93%
Capital efficient — spends only 0,59% of revenue on capex

Groei

Revenue Growth (5Y)
-59,33%
Onder sectorgemiddelde (1,82%)
Revenue (1Y)-78,26%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROIC-58,86%
Net Margin2848,63%
Op. Margin-712,66%

Veiligheid

Debt / Equity
N/A
Current Ratio3,71
Interest Coverage-5,24

Waardering

PE (TTM|NTM)
0,16 | -0,70
Boven sectorgemiddelde (-1,49)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1385 peers)
Metriek Aandeel Sector Mediaan
P/E 0,2 -1,5
P/B — 1,6
ROE % — -54,0
Net Margin % 2848,6 -41,5
Rev Growth 5Y % -59,3 1,8
D/E — 0,3

Koersdoel Analisten

1 analist
Buy
Huidig
€ 7,17
+499.7%
Koersdoel
€ 43,00
€ 43,00
€ 43,00
€ 43,00
Vooruitzicht
Forward K/W -0,70
Forward WPA -€ 10,25
Omzet Sch. 5,15 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 10,25
-€ 11,54 – -€ 8,96
 5,15 M 2
FY2026 -€ 13,54
-€ 15,80 – -€ 11,28
 5,15 M 2

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 3,89 -€ 3,51 +9,7%
Q32025 -€ 4,01 € 49,61 +1338,7%
Q22025 € 1,00 -€ 1,88 -288,0%
Q12025 € 0,50 € 1,25 +150,0%

All Fundamental Metrics
Growth
Revenue Growth (1Y) -78,26% Revenue Growth (3Y) -79,12%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -59,33% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 6,44 M Net Income (TTM) 183,45 M
ROE N/A ROA 116,45%
Gross Margin N/A Operating Margin -712,66%
Net Margin 2848,63% Free Cash Flow (TTM) -4,81 M
ROIC -58,86% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 3,71
Interest Coverage -5,24 Asset Turnover 0,04
Working Capital 97,45 M Tangible Book Value -17,03 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 0,16 Forward P/E -0,70
P/B Ratio N/A P/S Ratio 4,52
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 5,65 Fwd Earnings Yield N/A
FCF Yield -16,54%
Market Cap 29,10 M Enterprise Value -13,88 M
Per Share
EPS (Diluted TTM) 45,37 Revenue / Share 1,59
FCF / Share -1,19 OCF / Share -1,18
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0,59% FCF Conversion -2,62%
SBC-Adj. FCF -17,89 M Growth Momentum -18,93

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 6,44 M 29,62 M 147,75 M 140,73 M 235,31 M
Net Income 183,45 M -47,58 M -284,23 M -293,65 M -290,02 M
EPS (Diluted) 45,37 -0,48 -2,92 -3,14 —
Gross Profit — — — — —
Operating Income -45,90 M -150,42 M -281,82 M -301,03 M -288,53 M
EBITDA — — — — —
R&D Expenses 23,52 M 95,69 M 282,86 M 296,79 M 387,04 M
SG&A Expenses 27,71 M 49,33 M 115,25 M 124,69 M 123,93 M
D&A — — — — —
Interest Expense 8,76 M 8,25 M 15,53 M 1,44 M 1,08 M
Income Tax -90.000,0 -269.000,0 3.000,0 358.000,0 347.000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 119,59 M 214,53 M 423,53 M 610,09 M 773,82 M
Total Liabilities 115,12 M 398,16 M 585,73 M 611,57 M 544,71 M
Shareholders' Equity -30,04 M -225,60 M -204,17 M -21,45 M 209,15 M
Total Debt 75,00 M — — — —
Cash & Equivalents 47,87 M 50,48 M 113,69 M 155,70 M 171,22 M
Current Assets 99,07 M 196,51 M 331,56 M 492,83 M 474,06 M
Current Liabilities 29,24 M 133,31 M 217,67 M 273,56 M 225,50 M